Latest Headlines

Latest Headlines

German researchers tie CTC presence to breast cancer survival odds

Evidence is mounting that circulating tumor cells in the bloodstream, also known as CTCs, are a viable cancer biomarker tool. A team in Germany produced new evidence that their presence, or absence, may be an effective way to measure the survival chance of patients with early breast cancer.

What we learned from the big ASCO cancer drug data dump

Wednesday night's big round of ASCO news highlighted a few key memes with major implications for cancer drug development and everyone who works in the field. Overall, there were no big surprises in the news. And that's news in itself.

Counsyl, armed with $28M, begins big rollout of BRCA and other predictive genetic tests

California genetic testing startup Counsyl is launching BRCA and other predictive diagnostic tests. Crucially, $28 million in new Series D Financing will help kick all of this into high gear.

Ohio team touts promise of esophageal cancer biomarker and noninvasive screening test

A team of Ohio researchers has affirmed the viability of a new biomarker that could enable earlier diagnosis of esophageal cancer, along with a noninvasive test that screens for it.

Biocept's new pharma industry cancer biomarker service sparks Nasdaq gains

Biocept Laboratories' modest debut on the public markets in early February preceded a stock decline of more than 50% over the last few months. The week of April 28, however, Biocept's stock climbed more than 21% through Thursday after execs disclosed a promising new biomarker development service targeted to pharmaceutical companies.

Veracyte seals deal that opens Brazil market for its thyroid cancer Dx tech

Veracyte scored a major partnership deal with a large medical/diagnostic center that will help expand the reach of its signature thyroid cancer diagnostic technology throughout Brazil.

A certain protein marks tumors that will resist Astellas' prostate cancer drug Xtandi

As Astellas Pharma and Medivation work to broaden the reach of their prostate cancer drug Xtandi, researchers have identified a biomarker that could help proactively spot patients for whom the treatment will not work.

MDxHealth broadens reach of prostate cancer Dx with new U.S. PPO deal

MDxHealth will ally with a Texas-based provider network in a deal that will greatly expand the reach of its signature prostate cancer molecular diagnostic test to millions of additional patients.

Eventus attracts $2.72M for breast cancer Dx testing and commercial expansion

Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests.

3-D printed tumor mimics cancer better than 2-D model

A team of researchers from the U.S. and China has used 3-D printing to create a realistic model of a cancerous tumor.